Zentalis Pharmaceuticals Statistics
Total Valuation
ZNTL has a market cap or net worth of $287.59 million. The enterprise value is $114.49 million.
Important Dates
The next estimated earnings date is Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ZNTL has 71.19 million shares outstanding. The number of shares has increased by 0.34% in one year.
| Current Share Class | 71.19M |
| Shares Outstanding | 71.19M |
| Shares Change (YoY) | +0.34% |
| Shares Change (QoQ) | -1.95% |
| Owned by Insiders (%) | 2.16% |
| Owned by Institutions (%) | 52.31% |
| Float | 48.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.57 |
| P/TBV Ratio | 1.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.19, with a Debt / Equity ratio of 0.21.
| Current Ratio | 6.19 |
| Quick Ratio | 6.01 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -51.93% and return on invested capital (ROIC) is -31.78%.
| Return on Equity (ROE) | -51.93% |
| Return on Assets (ROA) | -27.88% |
| Return on Invested Capital (ROIC) | -31.78% |
| Return on Capital Employed (ROCE) | -65.24% |
| Weighted Average Cost of Capital (WACC) | 13.33% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.17M |
| Employee Count | 106 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ZNTL has paid $562,000 in taxes.
| Income Tax | 562,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +208.40% in the last 52 weeks. The beta is 1.98, so ZNTL's price volatility has been higher than the market average.
| Beta (5Y) | 1.98 |
| 52-Week Price Change | +208.40% |
| 50-Day Moving Average | 3.95 |
| 200-Day Moving Average | 2.56 |
| Relative Strength Index (RSI) | 56.56 |
| Average Volume (20 Days) | 1,207,687 |
Short Selling Information
The latest short interest is 4.98 million, so 7.00% of the outstanding shares have been sold short.
| Short Interest | 4.98M |
| Short Previous Month | 5.02M |
| Short % of Shares Out | 7.00% |
| Short % of Float | 10.26% |
| Short Ratio (days to cover) | 5.52 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -142.10M |
| Pretax Income | -123.57M |
| Net Income | -124.13M |
| EBITDA | -141.48M |
| EBIT | -142.10M |
| Earnings Per Share (EPS) | -$1.74 |
Full Income StatementBalance Sheet
The company has $211.76 million in cash and $38.65 million in debt, giving a net cash position of $173.11 million or $2.43 per share.
| Cash & Cash Equivalents | 211.76M |
| Total Debt | 38.65M |
| Net Cash | 173.11M |
| Net Cash Per Share | $2.43 |
| Equity (Book Value) | 182.68M |
| Book Value Per Share | 2.57 |
| Working Capital | 182.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$125.57 million and capital expenditures -$34,000, giving a free cash flow of -$125.60 million.
| Operating Cash Flow | -125.57M |
| Capital Expenditures | -34,000 |
| Depreciation & Amortization | 628,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -125.60M |
| FCF Per Share | -$1.76 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |